UNSPSC 51282908: Cadrofloxacin

This classification denotes a quinolone antibiotic with the molecular formula C19H20F3N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1YOQ7J9ACY, chemically known as 128427-55-4 (monohydrochloride, s isomer) but generally known as cadrofloxacin, which bears US NIH Compound Identifier 189912. The term CADROFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, List 43). Most nations schedule cadrofloxacin under HS 29335995 and SITC 51576.

As of Q4 2014, CADROFLOXACIN remains the US FDA Preferred Term for this commodity. Cadrofloxacin bears US NLM identifiers UMLS ID C1454081 and NCI Concept Code C76229. SMILES: CC1CN(CCN1)C2=C(C=C3C(=C2OC(F)F)N(C=C(C3=O)C(=O)O)C4CC4)F.

UNSPSC 51282908 Cadrofloxacin is a Commodity code that nominally refers to a specific fluoroquinolone antibiotic, yet the recent state and local opportunities tagged under it show little activity directly aligned with that narrow product scope. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride—related but distinct fluoroquinolones—totaling $2,999,999.11 over 12 months with two renewal options. A second opportunity, posted by Seminole County, Florida in June 2026, sought Naloxone and drug deactivation systems, which fall outside the antibiotic category entirely. The issuing bodies reflect typical state and local procurement patterns: a state health department using cooperative purchasing (MMCAP Infuse piggyback) and a county government pursuing community health supplies through competitive bidding.

The code shows activity concentrated in Florida and Illinois, though the geographic signal is weak given only two records, neither of which directly targets cadrofloxacin procurement. The Illinois contract, an IFB award completed in August 2026, demonstrates how state health agencies bundle pharmaceuticals through consortium agreements; the Seminole County opportunity, an IFB posted June 30, 2026 with a July 26, 2026 response deadline, reveals county health systems buying emergency-response and harm-reduction supplies rather than fluoroquinolones. The mismatch between the code's nominal scope and actual recent purchasing activity suggests this Commodity code sees limited direct use or is being misapplied in state and local procurement systems. Firms pursuing fluoroquinolone sales to state and local health bodies may find greater clarity and volume under broader pharmaceutical Family or Class codes rather than this specific product designation.